Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
06/2003
06/03/2003US6573302 Topical carrier wherein the topical carrier comprises a member selected from the group comprising lavender oil, myristal myristate, and other preservatives including, hypericum perforatum arnica montana capric acid; and capsaicin and
06/03/2003US6573271 Following surgery or trauma or resulting in ocular diseases associated with choroidal neovascularization, such as age related macular degeneration and histoplasmosis syndrome
06/03/2003US6573253 Methods for the administration of amifostine and related compounds
06/03/2003US6573239 Compound comprising 15 to 26-residue peptide or peptide analogue which forms amphipathic alpha-helix in presence of lipids and exhibits specified lecithin:cholesterol acyltransferase activation activity
06/03/2003US6573238 A biodegradable microparticle by forming a coating of a viscous form of a polypeptide e.g., insulin-like growth factor, with a poly(alpha-hydroxy acid), a polyhydroxybutyric acid, a polycaprolactone, a polyorthoester or a polyanhydride
06/03/2003US6573096 Continuous cell lines which produce monospecific antibodies that specifically bind an epitope of a human dipeptidyl peptidase IV and thereby inhibit angiogenesis; use in treatment of cancer
06/03/2003US6573074 Methods for ansamitocin production
06/03/2003US6572906 Foods, beverages, cosmetics
06/03/2003US6572898 Electrolyte gels for maintaining hydration and rehydration
06/03/2003US6572893 Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
06/03/2003US6572892 Solid blend of hydrophobic wax, an oil and talc
06/03/2003US6572888 Controlled release lipoic acid
06/03/2003US6572887 Polysaccharide material for direct compression
06/03/2003US6572884 Parenteral Cisplatin emulsion
06/03/2003US6572881 Delivery of polynucleotides to cells; polylactam
06/03/2003US6572880 Methods and transdermal compositions for pain relief
06/03/2003US6572879 Formulations for transdermal delivery of pergolide
06/03/2003US6572874 Vaginal delivery of bisphosphonates
06/03/2003US6572873 Sclerosing liquid for blood vessels, varicose veins and other disorders involving venous malformation; injectable foam using high volume percentages of blood dispersible gases, thus avoiding use of potentially hazardous amounts of nitrogen
06/03/2003US6572867 Reducing plasma levels of anti-( alpha Gal(1,3)Gal) antibodies; nonimmunogenic polymers comprise alpha Gal(1,3) Gal moieties covalently linked to said polymer; cross-links are covalent tethers, derived from N-hydroxysulfosuccinimide
06/03/2003US6572861 Lecithin, oil in water emulsion and an amphiphilic surfactant; minimize local reactions to the vaccine
06/03/2003US6572849 Buffered and low pH; inhbits microbial growth within
06/03/2003US6572842 Preparation for dental treatment
06/03/2003US6572841 Composition and method for decreasing upper respiratory airway resistance
06/03/2003CA2282757C Opthalmic composition
06/03/2003CA2251912C Inclusion complexes of aryl-heterocyclic salts
06/03/2003CA2137910C Use of microcapsules as contrasting agents in colour doppler sonography
06/03/2003CA2108266C Convertible microemulsion formulations
06/03/2003CA2094275C Methods and compositions for the treatment of cell proliferation disorders
05/2003
05/30/2003WO2003044218A1 Methods and compositions for the treatment and diagnosis of cellular proliferative disorders using 32222
05/30/2003WO2003044187A2 Emulsion compositions
05/30/2003WO2003044080A1 Water-in-silicone emulsions
05/30/2003WO2003044076A1 Bioerodible poly(ortho esters) containing amine groups, and block copolymers containing them
05/30/2003WO2003044056A2 Chemically-modified human growth hormone conjugates
05/30/2003WO2003044031A1 Technetium or rhenium complexes, radiopharmaceutical products comprising them
05/30/2003WO2003043672A1 Preparations appropriate for cartilage tissue formation
05/30/2003WO2003043668A2 Conditioning solution for contact lenses
05/30/2003WO2003043662A1 Inclusion complex of taxol with 2-hydroxypropyl-beta-cyclodextrin
05/30/2003WO2003043661A1 Preparation compositions containing acid-unstable physiologically acitve compounds and process for producing the same
05/30/2003WO2003043660A2 Composition for stabilizing hyaluronic acid
05/30/2003WO2003043659A1 Edible film
05/30/2003WO2003043657A1 Topical delivery of codrugs
05/30/2003WO2003043647A2 A plant extract active as an immunostimulating agent
05/30/2003WO2003043638A1 Coated particulate cefuroxime axetil compositions
05/30/2003WO2003043633A1 Use of an ascomycin for the treatment of blepharitis
05/30/2003WO2003043631A2 Method for identification of tumor targeting enzymes
05/30/2003WO2003043628A1 Medicament for the treatment of viral skin and tumour diseases
05/30/2003WO2003043620A1 A pharmaceutical composition for dermal application
05/30/2003WO2003043612A1 Micronized film-forming powder comprising an active substance
05/30/2003WO2003043608A1 Process for the preparation of tablets comprising s-adenosylmethionine
05/30/2003WO2003043606A1 Pharmaceutical formulation comprising bicalutamide
05/30/2003WO2003043604A1 Method for preparing a compound for interaction of active substances with a porous support using supercritical fluid
05/30/2003WO2003043586A2 Compositions for sustained action product delivery
05/30/2003WO2003043585A2 Improved particulate compositions for pulmonary delivery
05/30/2003WO2003043583A2 Treatment of immunological disorders using anti-cd30 antibodies
05/30/2003WO2003043574A2 Pharmaceutical compositions in particulate form
05/30/2003WO2003032728A3 Methods for preventing or reversing asthma and compositions useful therefor
05/30/2003WO2003028697A3 Liposome loading with metal ions
05/30/2003WO2003013478A3 Method of encapsulating an active substance
05/30/2003WO2003005952A3 Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
05/30/2003WO2002064132A3 Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
05/30/2003WO2002060384A3 Pharmaceutical formulation
05/30/2003WO2002058624A3 In situ generation allicin for the treatment of cancer and infectious diseases
05/30/2003WO2002048372A3 Target enzymes
05/30/2003WO2002047717A9 Targeted enzyme prodrug therapy
05/30/2003WO2002036160A3 Method for obtaining antigenic structures enhancing specific cross reactivity
05/30/2003WO2002031025A9 Biodegradable poly(beta-amino esters) and uses thereof
05/30/2003WO2002020090A3 Pharmaceutical compositions
05/30/2003WO2001080823A3 Composition exhibiting enhanced formulation stability and delivery of tropical active ingredients
05/30/2003CA2468170A1 Method for identification of tumor targeting enzymes
05/30/2003CA2468018A1 Micronized film-forming powder comprising an active substance
05/30/2003CA2467731A1 Chemically-modified human growth hormone conjugates
05/30/2003CA2467559A1 Topical delivery of codrugs
05/30/2003CA2467549A1 Use of an ascomycin for the treatment of blepharitis
05/30/2003CA2467242A1 Treatment of immunological disorders using anti-cd30 antibodies
05/30/2003CA2467104A1 A plant extract active as an immunostimulating agent
05/30/2003CA2466986A1 Pharmaceutical formulation comprising bicalutamide
05/30/2003CA2466982A1 Pharmaceutical compositions in particulate form
05/30/2003CA2465779A1 Compositions for sustained action product delivery
05/30/2003CA2463250A1 Edible film
05/30/2003CA2463179A1 Bioerodible poly(ortho esters) containing amine groups, and block copolymers containing them
05/30/2003CA2413224A1 Aqueous solution of ascorbic acid and method for producing same
05/29/2003US20030100942 Hydrogel for the therapeutic treatment of aneurysms
05/29/2003US20030100752 With various substitutents in the 12- and 17-positions of the porphyrin skeleton; atherosclerosis, restenosis
05/29/2003US20030100694 Hydrophilic polymers and methods of preparation
05/29/2003US20030100611 Delivery of gabapentin in a gastric retained dosage form for the treatment of epilepsy and other diseases
05/29/2003US20030100609 Orally ingesting a quantity of calcium formate sufficient to improve calcium balance or retention
05/29/2003US20030100595 Oral dosage form of a sulfonamide prodrug
05/29/2003US20030100574 Tricyclic 3,4-propinoperhydropurines; uses thereof for blocking neuronal transmission
05/29/2003US20030100566 Sustained release ranolazine formulations
05/29/2003US20030100509 Injectable solution of an LHRH antagonist
05/29/2003US20030100487 Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
05/29/2003US20030100115 Killing cells that lack tumor suppressor proteins; obtain cells, transform with preferential single stranded nucleotide sequence, monitor viability of cells
05/29/2003US20030100113 Plasmids for use in the transfer of nucleotide sequences into cells
05/29/2003US20030099760 Taste-improving agent and method of using the same
05/29/2003US20030099747 Thickened oil compositions of edible oil
05/29/2003US20030099741 Process for preparing chewing gum containing a nutritional supplemental
05/29/2003US20030099718 Nanocrystalline antimicrobial metals (noble metals)formed with atomic disorder are capable of releasing highly active clusters of the antimicrobial metal sufficient to cause microbiocidal effect; anti-inflammatory activity
05/29/2003US20030099714 Co-lyophilizing one or more peptides or peptide analogues, which are able to adopt an amphipathic conformation and one or more lipids in a solvent system to form a peptide/lipid product, which can be rehydrated to form the complex
05/29/2003US20030099711 Sustained release preparations
1 ... 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 ... 1712